Lorenzo Brunetti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8437813/publications.pdf

Version: 2024-02-01

45 papers	2,141 citations	257101 24 h-index	315357 38 g-index
48 all docs	48 docs citations	48 times ranked	3751 citing authors

#	Article	IF	Citations
1	Perturbed hematopoiesis in individuals with germline DNMT3A overgrowth Tatton-Brown-Rahman syndrome. Haematologica, 2022, 107, 887-898.	1.7	15
2	Systematic Profiling of DNMT3A Variants Reveals Protein Instability Mediated by the DCAF8 E3 Ubiquitin Ligase Adaptor. Cancer Discovery, 2022, 12, 220-235.	7.7	38
3	The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. Leukemia, 2022, , .	3.3	2
4	Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice. Leukemia, 2021, 35, 1949-1963.	3.3	10
5	CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia, 2021, 35, 75-89.	3.3	107
6	Prenatal diagnosis of familial hemophagocytic lymphohistiocytosis: morphological findings in the product of conception. Annals of Hematology, 2021, 100, 585-586.	0.8	0
7	How I diagnose and treatNPM1-mutated AML. Blood, 2021, 137, 589-599.	0.6	47
8	Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood, 2021, 137, 624-636.	0.6	147
9	CD123 Is Consistently Expressed on NPM1-Mutated AML Cells. Cancers, 2021, 13, 496.	1.7	20
10	Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML. Leukemia, 2021, 35, 2552-2562.	3.3	25
11	Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field. Leukemia, 2021, 35, 3113-3126.	3.3	22
12	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. Cancer Discovery, 2021, 11, 3198-3213.	7.7	38
13	Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. Blood, 2021, 138, 2696-2701.	0.6	30
14	Modeling IKZF1 lesions in B-ALL reveals distinct chemosensitivity patterns and potential therapeutic vulnerabilities. Blood Advances, 2021, 5, 3876-3890.	2.5	6
15	PU.1 subcellular localization in acute myeloid leukaemia with mutated NPM1. British Journal of Haematology, 2020, 188, 184-187.	1.2	10
16	Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion. Cell Stem Cell, 2020, 27, 326-335.e4.	5.2	25
17	Large-scale GMP-compliant CRISPR-Cas9â€“mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Advances, 2020, 4, 3357-3367.	2.5	27
18	TFEB regulates murine liver cell fate during development and regeneration. Nature Communications, 2020, 11, 2461.	5.8	32

#	Article	IF	Citations
19	Itâ€™s All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice. Cancer Cell, 2020, 37, 267-269.	7.7	20
20	Response to: â€œCytoplasmic dislocation of NPM1 and PU.1 in NPM1â€mutated leukemia is obscured by paraformaldehyde fixationâ€. British Journal of Haematology, 2020, 189, 577-578.	1.2	0
21	NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood, 2020, 136, 1707-1721.	0.6	152
22	Effect of the COVIDâ€19ÂPandemic on Laboratory and Clinical Research: A Testimony and a Call to Action From Researchers. HemaSphere, 2020, 4, e499.	1.2	14
23	Aerobic Plus Resistance Exercise in Obese Older Adults Improves Muscle Protein Synthesis and Preserves Myocellular Quality Despite Weight Loss. Cell Metabolism, 2019, 30, 261-273.e6.	7.2	77
24	Nutrientâ€sensitive transcription factors <scp>TFEB</scp> and <scp>TFE</scp> 3 couple autophagy and metabolism to the peripheral clock. EMBO Journal, 2019, 38, .	3.5	58
25	New insights into the biology of acute myeloid leukemia with mutated NPM1. International Journal of Hematology, 2019, 110, 150-160.	0.7	30
26	Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1511-E1519.	3.3	35
27	Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Journal of Visualized Experiments, 2018, , .	0.2	23
28	Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell, 2018, 34, 499-512.e9.	7.7	209
29	Precise Modeling of IKZF1 Alterations in Human B-Cell Acute Lymphoblastic Leukemia Cell Lines Reveals Distinct Chemosensitivity, Homing, and Engraftment Properties. Blood, 2018, 132, 549-549.	0.6	1
30	Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia, 2017, 31, 1238-1240.	3.3	37
31	DNMT3A in Leukemia. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a030320.	2.9	135
32	DNA epigenome editing using CRISPR-Cas SunTag-directed DNMT3A. Genome Biology, 2017, 18, 176.	3.8	153
33	Abstract 1031: Nuclear relocalization of NPM1c induces terminal differentiation and cell growth arrest. , 2017, , .		0
34	Acute Myeloid Leukemia with Mutated NPM1 Is Dependent on the Cytoplasmic Localization of NPM1c. Blood, 2017, 130, 877-877.	0.6	0
35	Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. Cell Reports, 2016, 17, 1453-1461.	2.9	223
36	Two-Pronged Cell Therapy for B-Cell Malignancies: Engineering NK Cells to Target CD22 and Redirect Bystander T Cells to CD19. Blood, 2016, 128, 4560-4560.	0.6	4

#	Article	IF	Citations
37	Fast and Efficient Gene Editing in Human Hematopoietic Cells. Blood, 2016, 128, 4704-4704.	0.6	0
38	Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. British Journal of Haematology, 2015, 170, 305-322.	1.2	36
39	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood, 2015, 125, 3455-3465.	0.6	124
40	Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 2015, 373, 1180-1182.	13.9	56
41	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. Blood, 2010, 116, 3907-3922.	0.6	100
42	CD200/OX2, a cell surface molecule with immunoâ€regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. British Journal of Haematology, 2009, 145, 665-667.	1.2	51
43	Acute Myeloid Leukemia with Mutated NPM1 Presenting with Life-Threatening, Either Arterial or Venous, Thromboembolism: a Report of 4 Cases.. Blood, 2009, 114, 4135-4135.	0.6	0
44	Dissecting the Hierarchical Level of Hematopoietic Progenitors' Involvement in AML with NPM1 Gene Mutation and Their Engraftment Potential in Immunocompromised Mice.. Blood, 2009, 114, 480-480.	0.6	0
45	CD200: a New Target for Immunotherapy in Hematologic Malignancies.. Blood, 2008, 112, 1598-1598.	0.6	1